India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
The combined entity will leverage its complementary strengths to deliver unparalleled solutions in protein purification and stabilization
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Subscribe To Our Newsletter & Stay Updated